Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Impact of lymph node ratio on survival and recurrence outcomes in oral squamous cell carcinoma (CROSBI ID 320924)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Mamić, Matija ; Lucijanić, Marko ; Lorencin, Mia ; Suton, Petar ; Lukšić, Ivica Impact of lymph node ratio on survival and recurrence outcomes in oral squamous cell carcinoma // International journal of oral and maxillofacial surgery, 51 (2022), 10; 1257-1263. doi: 10.1016/j.ijom.2022.01.009

Podaci o odgovornosti

Mamić, Matija ; Lucijanić, Marko ; Lorencin, Mia ; Suton, Petar ; Lukšić, Ivica

engleski

Impact of lymph node ratio on survival and recurrence outcomes in oral squamous cell carcinoma

Growing evidence supports the lymph node ratio (LNR) as a prognostic factor for survival in patients with oral squamous cell carcinoma (OSCC). However, there is a lack of data regarding its association with recurrence outcomes. Data on 163 patients with OSCC who underwent primary surgical treatment at a tertiary centre between January 2009 and December 2015 were collected retrospectively and analysed. Receiver operating characteristic curve analysis was performed to determine optimal cut-off values for the survival analyses. Survival endpoints were disease progression/relapse for disease-free time (DFT), freedom from loco-regional recurrence (FLR), and freedom from distant metastasis (FDM), and as death from any cause for overall survival (OS). Patients with a lower LNR were found to have significantly superior DFT (LNR < 14%, P < 0.001), FLR (LNR <14%, P < 0.001), FDM (LNR <16%, P = 0.004), and OS (LNR <7%, P = 0.004) in comparison to patients with a higher LNR. LNR is a good predictor of survival and recurrence outcomes in OSCC

lymph node ratio ; lymphatic metastasis ; mouth neoplasms ; neoplasm staging ; survival analysis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

51 (10)

2022.

1257-1263

objavljeno

0901-5027

1399-0020

10.1016/j.ijom.2022.01.009

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost